Novel strategies for discovering inhibitors of Dengue and Zika fever

Expert Opinion on Drug Discovery

Volumn 11, Issue 10, 2016, Pages 921-923

  Makhluf, Huda ^a,b   Kim, Kenneth ^a   Shresta, Sujan ^a  

^a LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY   (United States)

^b NATIONAL UNIVERSITY   (United States)

Author keywords

Dengue virus; Zika virus and antivirals

Indexed keywords

ALPHA GLUCOSIDASE I INHIBITOR; ALPHA GLUCOSIDASE INHIBITOR; ANTIVIRUS AGENT; CASTANOSPERMINE 6 BUTYRATE; IMINOSUGAR; PROTEIN; UNCLASSIFIED DRUG; UV 12; UV 4B;

ANTIVIRAL THERAPY; DENGUE; DENGUE VIRUS; EDITORIAL; HUMAN; INNATE IMMUNITY; MOUSE MODEL; NONHUMAN; PRIORITY JOURNAL; PROTEIN TARGETING; VIRUS LOAD; ZIKA FEVER; ANIMAL; DRUG DESIGN; DRUG DEVELOPMENT; DRUG REPOSITIONING; PROCEDURES; VIROLOGY;

ANIMALS; ANTIVIRAL AGENTS; DENGUE; DRUG DESIGN; DRUG DISCOVERY; DRUG REPOSITIONING; HUMANS; ZIKA VIRUS INFECTION;

EID: 84979639101     PISSN: 17460441     EISSN: 1746045X     Source Type: Journal    
DOI: 10.1080/17460441.2016.1212013     Document Type: Editorial

References (15)

1. S.Bhatt, P.W.Gething, O.J.Brady, et al. The global distribution and burden of dengue. Nature Publishing Group. 2013;496:504–507. doi:10.1038/nature12060•• This paper reports that the global burden of DENV infection is significantly higher than current estimates.
2. D.Wyles Antiviral resistance and the future landscape of hepatitis C virus infection therapy. J Infect Dis. 2013;S 33- S 39. doi:10.1093/infdis/jis761.
3. E.De Clercq. Anti-HIV drugs:25 compounds approved within 25 years after the discovery of HIV. Int J Antimicrob Agents. 2009;33:307–320. doi:10.1016/j.ijantimicag.2008.10.010.
4. E.Plummer, M.D.Buck, M.Sanchez, et al. Dengue virus evolution under a host-targeted antiviral. J Virol. 2015;89:5592–5601. doi:10.1128/JVI.00028-15.
5. S.Pheng, Q.Wang, C.G.Noble, et al. Ten years of dengue drug discovery:progress and prospects. Antiviral Res. 2013;100:500–519. doi:10.1016/j.antiviral.2013.09.013•• This paper provides a considerable review of a decade of dengue drug discoveries with substantial contributions from the Novartis Institute of Tropical Diseases.
6. S.Watanabe, K.W.Chan, G.Dow, et al. Optimizing celgosivir therapy in mouse models of dengue virus infection of serotypes 1 and 2:the search for a window for potential therapeutic ef fi cacy. Antiviral Res. 2016;127:10–19. doi:10.1016/j.antiviral.2015.12.008•• This paper provides a follow-up to the initial Celgocivir clinical trial and discusses its clinical efficacy.
7. K.L.Warfield, E.Plummer, D.S.Alonzi, et al. Influenza V. A novel iminosugar UV-12 with activity against the diverse Viruses influenza and dengue (Novel iminosugar antiviral for influenza and dengue). Viruses. 2015;7:2404–2427.
8. N.S.Heaton, N.Moshkina, R.Fenouil, et al. Targeting viral Proteostasis limits influenza virus, HIV, and dengue virus. Infection. 2016;44:46–58. doi:10.1007/s15010-015-0856-9.
9. S.Taguwa, K.Maringer, X.Li, et al. Defining Hsp70 subnetworks in dengue virus replication reveals key vulnerability in flavivirus infection. Cell. 2015;163:1108–1123. doi:10.1016/j.cell.2015.10.046.
10. A.K.Pinto, J.D.Brien, C.K.Lam, et al. Defining new therapeutics using a more immunocompetent mouse model of antibody-enhanced dengue virus infection. MBio. 2015;6:1–13. doi:10.1128/mBio.01316-15.
11. Y.Suzuki, W.Chin, Q.E.Han, et al. Characterization of RyDEN (C19orf66) as an interferon-stimulated cellular inhibitor against dengue virus replication. PLoS Pathog. 2016;12:1–37. doi:10.1371/journal.ppat.1005357.
12. W.W.Tang, R.Grewal, S.Shresta. Influence of antibodies and T cells on dengue disease outcome:insights from interferon receptor-deficient mouse models. Curr Opin Virol. 2015;13:61–66. doi:10.1016/j.coviro.2015.04.007• This paper highlights key findings using interferon receptor deficient mouse models in an effort to dissect the contributions of antibodies and T cells to DENV infection outcomes.
13. C.Deligny, M.De Bandt, V.Dehlinger, et al. Dengue fever in patients under biologics. J Clin Virol. 2014;61:442–443. doi:10.1016/j.jcv.2014.08.027.
14. National University Hospital, Singapore; Duke-NUS Graduate Medical School; Singapore General Hospital. Ketotifen as a treatment for vascular leakage during dengue fever (KETODEN). ClinicalTrials.gov [Internet]. Bethesda (MD):National Library of Medicine (US). 2000. [cited 2016 May18]. Available from:http://clinicaltrials.gov/show/NCT02673840 NLM Identifier:NCT02673840
15. J.G.Burel, S.H.Apte, D.L.Doolan. Systems approaches towards molecular profiling of human immunity. Trends Immunol. 2016;37:53–67. doi:10.1016/j.it.2015.11.006• This paper describes opportunities for utilizing systems immunology, departing from a reductionist approach to a more holistic powerful framework for unraveling the complexity of the immune system.